Current pharmaceutical design最新文献

{"title":"QSAR and Molecular Docking Studies on Uracil-Based Benzoic Acid and Ester Derivatives to Explore Novel Dipeptidyl Peptidase-4 Inhibitors.","authors":"Pradeep Pilania, Prithvi Singh","doi":"10.2174/0113816128331664250206113701","DOIUrl":"https://doi.org/10.2174/0113816128331664250206113701","url":null,"abstract":"<p><strong>Background: </strong>Today, diabetes mellitus (DM) is considered a major global health problem and, especially diabetes mellitus type-2 (T2DM), which accounts for 90-95% of all diabetes cases. Among the novel glucose-lowering agents, dipeptidyl peptidase-4 (DPP-4) inhibitors have been extensively studied in recent years.</p><p><strong>Objectives: </strong>This paper integrates a QSAR study and docking analysis of a series of uracil-based benzoic acid and ester derivatives as novel DPP-4 inhibitors.</p><p><strong>Methods: </strong>The correlation of chemical structure with the biological activity in CP-MLR led to the detection of eleven descriptors from various classes of Dragon descriptors for modeling the activity. The resulting QSAR model has been validated internally and externally using CP-MLR and PLS. Further, the applicability domain analysis revealed the acceptable predictivity of the highest significant model.</p><p><strong>Result: </strong>The best QSAR model displays the r2 Test value of 0.715, Q2 LOO value of 0.797 and Q2 L5O value of 0.809 and this model is used to predict novel compounds with high potency. Further docking study was executed using Autodock 4.2 against DPP-4 protein (PDB ID: 2RGU) that reflects the significant binding potential in newly proposed compounds.</p><p><strong>Conclusion: </strong>From the results, four new congeners have been predicted and validated with good inhibitory activity against DPP-4. Present work reflects that with further optimization of these scaffolds, more selective, potent, and bioavailable DPP-4 inhibitors can be developed for the treatment of T2DM.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem Cell Nanotechnology Applications as Drug Delivery Systems for Neurodegenerative Disorders.","authors":"Md Sadique Hussain, Prasanna Srinivasan Ramalingam, Ajay Singh Bisht","doi":"10.2174/0113816128377684250310073151","DOIUrl":"https://doi.org/10.2174/0113816128377684250310073151","url":null,"abstract":"","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vegetable Oils in Skin Whitening - A Narrative Review.","authors":"Julia Capp Zilles, Marya Alexandrina Vallenot Lemos, Miriam Anders Apel, Irene Clemes Kulkamp-Guerreiro, Aline Rigon Zimmer, Renata Vidor Contri","doi":"10.2174/0113816128361413250107114203","DOIUrl":"https://doi.org/10.2174/0113816128361413250107114203","url":null,"abstract":"<p><p>Plants are a source of a variety of compounds, such as vegetable oils, which are rich in fatty acids and possess skin-whitening properties. Considering the hyperpigmentation treatment challenges (lack of efficacy or aggressiveness), the constant search for new whitening substances is necessary. Given vegetable oils' potential and application in dermatological and cosmetic products, we reviewed the scientific literature on vegetable oils with skin depigmenting activity. It was observed that a variety of species (Adansonia digitata, Arctium lappa, Argania spinosa, Astrocaryum vulgare, Bertholletia excelsa, Borago officinalis, Camellia oleifera, Cucurbita moschata, Euterpe oleraceae, Hevea brasiliensis, Moringa oleifera, Nicotiana tabacum, Oenocarpus bataua, Oenothera biennis, Panax ginseng, Passiflora edulis, Pentaclethra macroloba, Perilla frutescens, Sapindus mukorossi, Taiwanese species Taichung selective No. 4 (TCS4) (Adlay bran), Torreya grandis) were evaluated in vitro regarding their skin whitening properties. All the studies demonstrated that the oils have skin whitening properties and that the oils' activity is related to their composition. The harvesting period, as well as the extraction method, impact on the oils' properties, hence in their activity. The use of vegetable oils can have advantages over an isolated compound as their components can have synergistic or adding effects. When conducting skin whitening experiments, it is recommended to employ multiple assays because vegetable oils can influence skin whitening through various mechanisms. Furthermore, more clinical trials should be encouraged, considering the potential of vegetable oils as skin-lightening ingredients. More innovative and effective formulations can be obtained using vegetable oils for skin whitening purposes.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solid Lipid Nanoparticles for the Management of Hypertension: Advancements and Challenges.","authors":"Avinaba Das, B H Jaswanth Gowda, Umme Hani, Karthika Paul, Mohammed Gulzar Ahmed, Gholamreza Abdi, Sharmin Sultana Shimu","doi":"10.2174/0113816128337166241219081400","DOIUrl":"https://doi.org/10.2174/0113816128337166241219081400","url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) remain a global health challenge, with hypertension emerging as a leading risk factor. Hypertension, characterized by elevated arterial blood pressure (BP), significantly increases the risk of stroke and other CVDs. Despite advancements in antihypertensive medication, the effectiveness of hypertension treatment is often hindered by poor bioavailability and limited drug efficacy. In this quest, nanoparticles (NPs) offer a promising avenue for addressing the limitations associated with conventional antihypertensive drugs in hypertension treatment. Among several NPs, solid lipid nanoparticles (SLNs) have emerged as a potential candidate, presenting a multifaceted approach to revolutionize drug delivery within this domain. SLNs, characterized by a lipophilic matrix and stabilized by surfactants, offer scalability and compatibility with biological systems compared to several polymer-based nanosystems. By encapsulating antihypertensive drugs, SLNs enhance drug solubility and bioavailability and provide sustained release, thereby improving treatment efficacy. In this context, this review provides an overview of the pathophysiology of hypertension and the role of SLNs in drug delivery. Various preparation techniques of SLNs are discussed, highlighting their versatility and potential in pharmaceutical applications. Furthermore, the role of SLNs in the management of hypertension is thoroughly examined, with a focus on enhancing the physicochemical properties of antihypertensive drugs. Overall, SLNs represent a promising strategy for optimizing hypertension treatment by addressing the limitations of conventional drug delivery systems. By enhancing drug stability, bioavailability, and efficacy, SLNs offer new possibilities for improving patient outcomes and reducing the global burden of cardiovascular diseases. This review aims to contribute to the ongoing research and development of innovative therapies for hypertension management.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Membrane Simulations in Probiotics and Gut Microbiome Interaction Research: The Current Trends and Insights.","authors":"Yashika Gupta, Bhavya Sharma, Chakresh Kumar Jain","doi":"10.2174/0113816128357214250221053909","DOIUrl":"https://doi.org/10.2174/0113816128357214250221053909","url":null,"abstract":"<p><p>The gut microbiome, a complex and diverse microbial ecosystem, plays a pivotal role in maintaining host health by regulating physiological balance and preventing disease. Probiotics, live beneficial microorganisms, have shown potential in modulating the gut microbiota through mechanisms such as competitive exclusion of pathogens, enhancement of mucosal immunity, and regulation of microbial metabolism. Recent advancements in membrane simulations offer a novel approach to studying these interactions at the molecular level. By employing molecular dynamics (MD) and coarse-grained models, these simulations provide insights into the structural and functional dynamics of bacterial membranes and their interactions with probiotics. This approach enables a deeper understanding of key processes, such as microbial metabolite transport, membrane permeability, and host response modulation, which are critical for maintaining gut homeostasis. Additionally, membrane simulations facilitate the exploration of microbial communication pathways, enhancing our knowledge of the molecular mechanisms underlying the beneficial effects of probiotics. As computational tools evolve, integrating membrane simulations with experimental approaches can accelerate the discovery of targeted probiotic therapies aimed at restoring microbial balance and optimizing gut health. This review underscores the significance of membrane simulations in advancing gut microbiome research, suggesting that future studies should focus on refining these computational models to bridge the gap between theoretical predictions and clinical applications. Through a synergistic approach, researchers can enhance the therapeutic potential of probiotics, leading to improved strategies for managing gut-related disorders with insightful knowledge of their interactions.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive Review.","authors":"Devesh U Kapoor, Bhupendra G Prajapati, Sankha Bhattacharya, Nidhi Jain Singhai, Rahul Maheshwari","doi":"10.2174/0113816128338217250114073640","DOIUrl":"https://doi.org/10.2174/0113816128338217250114073640","url":null,"abstract":"<p><p>The field of drug delivery has witnessed significant advancements with the emergence of nanocarriers and advanced delivery devices for parenteral administration. Nanocarriers, a prominent topic in drug delivery, are introduced with an emphasis on their significance and diverse applications A critical analysis compares conventional injectables with parenteral nanocarriers, focusing on identifying limitations and proposing innovative solutions to enhance their efficacy and stability. The subsequent discussion delves into advanced parenteral nanocarriers, including solid lipid nanoparticles, liposomes, polymeric nanoparticles, metallic nanoparticles, dendrimers, carbon nanotubes, and graphene. Each nanoparticle type is assessed based on its unique properties, advancements in research, and potential applications in parenteral drug delivery. Furthermore, advanced sterile drug delivery devices are explored, highlighting their role in enhancing precision and efficacy in parenteral administration. A comprehensive market analysis provides insights into current trends, key players, and future prospects in parenteral nanocarriers. Lastly, regulatory perspectives are discussed, focusing on the challenges and considerations in approving and regulating parenteral nanocarriers. The paper concludes with a summary of key findings and implications for future research and development in this rapidly evolving field of parenteral nanocarriers.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Anaplastic Lymphoma Kinase in Oncology: Identification and Computational Validation of Novel Inhibitors for Anaplastic Large Cell Lymphoma, Non-small Cell Lung Cancer, and Neuroblastoma.","authors":"Aftab Alam, Mohammed H Alqarni, Indrakant K Singh, Ahmed I Foudah, Neeraj Upmanyu, Mohamed F Balaha","doi":"10.2174/0113816128342778250218105338","DOIUrl":"https://doi.org/10.2174/0113816128342778250218105338","url":null,"abstract":"<p><strong>Background: </strong>Anaplastic Lymphoma Kinase (ALK) is implicated in several cancers, including anaplastic large cell lymphoma, non-small cell lung cancer, and neuroblastoma. Targeted inhibition of ALK represents a promising therapeutic strategy.</p><p><strong>Aims: </strong>This study aimed to identify and evaluate potential ALK inhibitors using virtual screening and computational analyses to determine their binding stability, affinity, and dynamic behavior, ultimately assessing their potential as therapeutic agents for ALK-driven cancers.</p><p><strong>Objective: </strong>The objective of this study was to identify potential ALK inhibitors using virtual screening techniques and to evaluate their binding affinities and stability through computational analyses.</p><p><strong>Methods: </strong>This study utilized virtual screening to identify potential ALK inhibitors from the MTiOpen Screen Diverse library and selected three compounds (24331480, 26536128, and 24353407) based on their binding affinities. These compounds underwent optimization using Density Functional Theory (DFT) and were redocked to confirm binding stability. Molecular dynamics simulations, hydrogen bond analysis, MM/PBSA calculations, and PCA-based free energy landscape analysis were also carried out.</p><p><strong>Results: </strong>The re-docking experiments confirmed the stable and strong binding affinities of the selected compounds to the ALK active site. Molecular dynamics simulations revealed stable interactions throughout the 200 ns simulation period. Hydrogen bond analysis demonstrated consistent hydrogen bonds between key residues and the inhibitors. MM/PBSA calculations indicated favorable binding free energies, suggesting strong binding affinities. Finally, PCA-based free energy landscape analysis highlighted energetically favorable binding modes.</p><p><strong>Conclusion: </strong>The identified compounds (24331480, 26536128, and 24353407) exhibited promising inhibitory potential against ALK. These findings warrant further experimental validation to confirm their potential as therapeutic agents for ALK-driven cancers.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-clinical Safety Study of Cold Atmospheric Plasma (CAP) Produced by an Inbuilt CAP Device and ROS Mediated Apoptotic Activity in Human Skin Melanoma Cells.","authors":"Ratul Chakraborty, Reetesh Borpatra Gohain, Punam Talukdar, Liza Changkakoti, Subir Biswas, Ashis K Mukherjee, Asis Bala","doi":"10.2174/0113816128335012250122221541","DOIUrl":"https://doi.org/10.2174/0113816128335012250122221541","url":null,"abstract":"<p><strong>Introduction: </strong>In recent decades, Cold Atmospheric Plasma (CAP) has become increasingly popular in healthcare for managing diseases, especially skin cancer. This study aimed to assess the preclinical safety of an indigenously developed dielectric barrier discharge-CAP device and its cytotoxic efficacy against melanoma cells while adhering to OECD 402 guidelines for acute dermal toxicity study. The safety evaluation includes ex vivo studies on mouse peritoneal exudates and in vivo acute dermal toxicity tests on Wistar rats.</p><p><strong>Methods: </strong>The ex vivo study of mice peritoneal cells treated for up to 120 seconds, showed a survival rate of over 90% up to 90 seconds of CAP treatment for applied voltage 18.6 kV at 20 kHz with no significant difference with control. In the acute dermal toxicity tests, CAP exposure for up to 30 seconds caused minimal inflammatory cell infiltration and no significant Dermal Inflammation Scoring (DIS) (<1).</p><p><strong>Results: </strong>The efficacy study against G361 human melanoma cells showed reduced cell viability by ~50% (MTT assay) upon 30 seconds of CAP treatment for applied voltage 24 kV at 20 kHz through ROS-mediated apoptosis, confirmed by a 3-fold increase in intracellular reactive oxygen species levels and nuclear fragmentation (4',6-diamidino-2-phenylindole staining). Annexin V/PI (propium iodide) staining further revealed ~30% apoptosis after 24 hours of incubation. These findings establish the developed DBD-CAP device is safe for rat skin exposure durations of up to 30 seconds and effective in inducing apoptosis in melanoma cells.</p><p><strong>Conclusion: </strong>This study supports CAP's optimization for clinical applications and its integration with existing therapies for enhanced outcomes. However, further study is needed to examine the possible risks associated with using CAP devices in the biomedical field.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Mini-Review on EGFR-Tyrosine Kinase Inhibitors and their Resistance Mechanisms.","authors":"Mohd Javed Naim, Abdul Samad","doi":"10.2174/0113816128349342250121053445","DOIUrl":"https://doi.org/10.2174/0113816128349342250121053445","url":null,"abstract":"<p><strong>Background: </strong>An essential component of cell development, proliferation, and survival is the transmembrane receptor known as the epidermal growth factor receptor (EGFR). Dysregulated EGFR signalling is an appealing pathway that has been linked to the genesis and progression of several cancer types. EGFR tyrosine kinase inhibitors (TKIs) are targeted drugs that show promise in the fight against cancer. EGFR tyrosine kinase inhibitors obstruct cancer growth and survival signalling pathways by blocking the receptor's tyrosine kinase domain. Patients with non-small cell lung cancer (NSCLC) that have EGFR mutations have shown increased progression-free survival and overall survival rates when treated with EGFR TKIs as compared to conventional chemotherapy, according to many clinical studies.</p><p><strong>Objectives: </strong>This review is aimed to present the journey of EGFR-tyrosine kinase inhibitors, their signalling cascade, and various resistant mechanisms.</p><p><strong>Methods: </strong>The literature search was carried out on electronic databases like PubMed, Medline, etc., by employing search keywords, such as EGFR, EGFR inhibitors, cancer, tyrosine kinase, etc., and data on EGFR signaling pathways and the types of potential inhibitors in a hierarchical manner, followed by various resistance mechanisms that have emerged, were collected.</p><p><strong>Results: </strong>Drug resistance is still an issue in long-term therapy of patients, even though EGFR TKIs provide substantial therapeutic advantages. Common routes of resistance to EGFR TKIs include acquired resistance mechanisms, which include the development of secondary EGFR mutations and the activation of alternative signalling pathways. To improve the therapeutic effectiveness of EGFR TKIs, future research will center on searching indicators of response and resistance, finding ways to employ these medicines most effectively, and creating new treatment approaches.</p><p><strong>Conclusion: </strong>This review provides insight into the use of EGFR kinase inhibitors for treating cancer patients and outlines potential advancements in current therapies to develop more effective molecules.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SNHG10: A Novel Long Non-coding RNA with Multifaceted Roles in Human Cancers.","authors":"Haodong He, Jingjie Yang, Yan Zhou, Lihan Chen, Chuyuan Liao, Ting Gong, Tongtong Li, Haoran Liu, Yunfei Pan, Pengbo Zhang, Xiaolan Li, Chengfu Yuan","doi":"10.2174/0113816128356231250212050707","DOIUrl":"https://doi.org/10.2174/0113816128356231250212050707","url":null,"abstract":"<p><p>Long non-coding RNAs (lncRNAs) are a type of RNA with a length of more than 200 nucleotides. They do not encode proteins but are crucial in regulating gene expression and affecting the malignant biological behavior of cancer. Small nucleolar RNA host gene 10 (SNHG10) is a novel lncRNA that plays a regulatory role in many malignant tumors. Several recent studies have shown that SNHG10 is aberrantly expressed in various forms of cancer. This instability is closely related to important tumorigenic processes, such as cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and chemotherapy resistance. SNHG10 has been reported to play a role through a variety of molecular mechanisms, including serving as a competing endogenous RNA (ceRNA), regulating epigenetic processes, and affecting immune responses and tumor microenvironment. Furthermore, SNHG10 is involved in metabolic reprogramming, immune evasion, and chromatin remodeling, highlighting its diverse roles in tumor biology. Due to the specificity and selectivity of its expression level, the potential of SNHG10 as a diagnostic biomarker and therapeutic target has attracted significant attention, and its correlation with the prognosis and treatment of various tumor types is of great significance. This review focuses on the biological function and molecular mechanism of SNHG10 and its relationship with various malignant tumors. In addition, this review highlights the potential of SNHG10 to improve precision oncology and develop novel cancer therapies by investigating its upstream regulators, downstream targets, and interactions with nuclear and cytoplasmic processes.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}